5-Amino-1MQ in the Peptides UK Market: NNMT Science, Evidence and Regulation
5-Amino-1MQ in the Peptides UK Market: NNMT Science, Evidence and Regulation
5-Amino-1MQ is a synthetic small-molecule inhibitor of nicotinamide N-methyltransferase, commonly abbreviated to NNMT. It is frequently grouped with research peptides by online sellers, but it is not a peptide. Published findings concerning body composition, glucose regulation, liver pathology and muscle function come from laboratory and animal studies rather than established human clinical trials.
Direct Answer
5-Amino-1MQ is the abbreviated commercial name for 5-amino-1-methylquinolinium, a positively charged aromatic small molecule studied as an inhibitor of nicotinamide N-methyltransferase.
NNMT is an enzyme that transfers a methyl group from S-adenosyl-L-methionine to nicotinamide, producing 1-methylnicotinamide and S-adenosyl-L-homocysteine. Researchers are interested in the enzyme because it connects nicotinamide metabolism, NAD-related pathways and the cellular methyl-donor system.
In cultured adipocytes and several mouse models, 5-Amino-1MQ reduced the NNMT activity marker 1-methylnicotinamide and was associated with changes in adiposity, glucose handling, liver histology and aged-muscle performance.
These findings are preclinical. No published, adequately controlled human trial establishing the safety, pharmacokinetics, effective exposure or clinical benefit of 5-Amino-1MQ was identified for this article. It is not an authorised UK medicine or an established weight-management treatment.
5-Amino-1MQ Key Points
The essential facts needed to interpret the compound without turning animal research into human claims.
What Is 5-Amino-1MQ?
5-Amino-1MQ is a synthetic inhibitor developed for research into the metabolic enzyme NNMT.
Its full chemical name is 5-amino-1-methylquinolinium. The structure is based on a quinoline ring containing a permanently methylated ring nitrogen and an amino group at the fifth position.
The methylated ring nitrogen gives the molecule a positive charge. Commercial research material is therefore commonly supplied with an oppositely charged counterion, such as iodide, to form an electrically neutral salt.
The compound was selected from a series of quinolinium-based molecules studied for cell permeability, enzyme selectivity and inhibition of NNMT.
The foundational pharmacology paper described 5-Amino-1MQ as a potent, membrane-permeable inhibitor with strong selectivity for NNMT compared with the other methyltransferases tested in that research programme.
Is 5-Amino-1MQ a Peptide?
No. It does not contain an amino-acid chain or peptide bonds.
A peptide is built from amino-acid residues joined through peptide bonds. BPC-157, KPV and Selank are examples of molecules that meet that structural description.
5-Amino-1MQ is a small aromatic organic molecule. The word “amino” in its chemical name refers to an amino functional group attached to the quinolinium ring. It does not mean that the substance is an amino-acid peptide.
This is more than a naming detail. Peptides and small molecules usually require different analytical methods, impurity assessments, formulation studies and stability programmes.
| Feature | 5-Amino-1MQ | Typical Research Peptide |
|---|---|---|
| Basic structure | Quinolinium ring system | Amino-acid chain |
| Peptide bonds | None | Present |
| Molecular size | Low-molecular-weight small molecule | Varies from short oligopeptides to larger proteins |
| Common identity testing | LC-MS, NMR, chromatography and counterion testing | LC-MS, peptide mapping, sequence and terminal-group testing |
| Main research classification | Enzyme inhibitor | Peptide ligand, analogue or signalling fragment |
Why 5-Amino-1MQ Appears in the Peptides UK Market
Commercial categories do not always reflect chemical classification.
5-Amino-1MQ frequently appears on the same websites as experimental peptides because both categories attract interest from laboratory-research, metabolic-science and biohacking audiences.
Search pages aimed at the Peptides UK market may place the compound beside GLP-1 analogues, mitochondrial peptides, growth-hormone-related substances and peptide blends.
This placement can create the false impression that 5-Amino-1MQ has been studied to the same extent as an authorised peptide medicine. It can also obscure the fact that there is no validated human use, dose, safety profile or approved indication.
Product descriptions may call it a fat-loss peptide, metabolic peptide or NAD peptide. None of these descriptions is chemically accurate.
A commercial category is not a scientific category
Inclusion in a Peptides UK catalogue does not turn 5-Amino-1MQ into a peptide and does not establish that it is suitable for human administration.
Molecular and Scientific Profile
The reported molecular weight depends on whether the charged compound or a complete salt is being described.
5-Amino-1-Methylquinolinium
PubChem lists the free positively charged component with the molecular formula C10H11N2+.
Nicotinamide N-Methyltransferase
NNMT is a cytosolic methyltransferase that uses S-adenosyl-L-methionine to methylate nicotinamide.
The principal product of that reaction is 1-methylnicotinamide.
| Preferred descriptive name | 5-amino-1-methylquinolinium |
|---|---|
| Common abbreviations | 5-Amino-1MQ, 5A1MQ, 5-AMQ and 5MQ |
| Chemical category | Quaternary quinolinium small molecule |
| Free-cation formula | C10H11N2+ |
| Approximate free-cation mass | Approximately 159.21 Da |
| Common iodide-salt formula | C10H11IN2 |
| Approximate iodide-salt mass | Approximately 286.11 g/mol |
| Primary research target | Nicotinamide N-methyltransferase |
| Clinical status | Investigational research compound with no identified UK marketing authorisation |
Free Cation, Iodide Salt and Product Naming
Different molecular weights may both be correct when they refer to different chemical presentations.
The 5-amino-1-methylquinolinium structure carries a positive charge. It therefore requires a counterion when supplied as a neutral solid salt.
Research papers may discuss the active quinolinium component without repeatedly naming the counterion. Commercial certificates may instead report 5-Amino-1MQ iodide and include the mass of the iodide ion.
This creates a common certificate-of-analysis problem. A laboratory may calculate concentration or purity using the free-cation molecular weight while the physical material is an iodide salt, or vice versa.
Other counterions should not be assumed equivalent without evidence. Counterion identity can affect molecular weight, elemental composition, solubility, crystallinity and analytical results.
What a certificate should make clear
The report should state whether the assay is calculated as the active 5-amino-1-methylquinolinium cation, the complete iodide salt or another declared salt form.
What Is Nicotinamide N-Methyltransferase?
NNMT lies at the intersection of nicotinamide metabolism and the cellular methyl-donor system.
Nicotinamide is a form of vitamin B3 and a precursor used within NAD salvage pathways. NAD participates in redox reactions, energy metabolism and the activity of several signalling enzymes.
NNMT transfers a methyl group from S-adenosyl-L-methionine, known as SAM, to nicotinamide. The reaction forms 1-methylnicotinamide and S-adenosyl-L-homocysteine.
Because the reaction consumes both nicotinamide and a methyl donor, changes in NNMT expression may influence the availability of metabolites associated with NAD turnover and methylation balance.
NNMT is expressed in several tissues, including liver, adipose tissue and skeletal muscle. Its role is tissue-dependent and should not be reduced to the idea that the enzyme is universally harmful.
NNMT is not simply a metabolic toxin
The enzyme and its products have physiological roles. Inhibiting an endogenous metabolic enzyme can create effects beyond the intended experimental target, particularly when human exposure and long-term safety have not been established.
How Is 5-Amino-1MQ Thought to Work in Research Models?
The proposed mechanism begins with reduced NNMT activity but extends into several interconnected pathways.
Reduced Formation of 1-Methylnicotinamide
Researchers use reduced 1-methylnicotinamide as a pharmacodynamic marker that NNMT activity has been inhibited.
In the foundational cell experiments, 5-Amino-1MQ reduced intracellular 1-methylnicotinamide in adipocyte-related systems.
Nicotinamide and NAD-Related Pathways
By reducing the methylation of nicotinamide, NNMT inhibition may leave more nicotinamide available for salvage into NAD-related pathways.
The original adipocyte research reported increased intracellular NAD following 5-Amino-1MQ exposure. This was a cell-system observation and should not be translated directly into claims of improved human energy, longevity or mitochondrial health.
SAM and Methylation Balance
NNMT uses SAM as a methyl donor. Changes in NNMT activity may therefore alter the relationship between SAM and S-adenosyl-L-homocysteine and influence methylation-related processes.
These pathways are complex. A change in a methyl-donor pool is not automatically beneficial and may vary between tissues.
Adipocyte Lipid Handling
In cultured adipocyte models, 5-Amino-1MQ was associated with reduced lipid accumulation and changes in cellular metabolic measurements.
These experiments provided a rationale for later mouse studies but did not establish a human fat-loss effect.
What Cell Research Shows
The earliest 5-Amino-1MQ findings came from enzyme assays and adipocyte-related laboratory systems.
NNMT Inhibition
Quinolinium compounds were screened for their ability to inhibit NNMT. 5-Amino-1MQ was selected for further work because of its potency, permeability and selectivity in the tested systems.
Intracellular Target Access
The compound was able to enter the cell models used in the foundational study and reduce the intracellular target-engagement marker 1-methylnicotinamide.
NAD-Related Measurements
Treated adipocyte systems showed changes including higher intracellular NAD under the experimental conditions.
Lipid Accumulation
Researchers reported reduced lipid accumulation during selected adipocyte-differentiation and lipogenesis experiments.
What these experiments cannot establish
A change in cultured fat cells does not prove safe weight loss, improved metabolic health or an effective treatment in people. Cell systems do not reproduce digestion, organ distribution, immune responses, long-term toxicity or human behaviour.
Foundational Research in Diet-Induced Obese Mice
The frequently repeated weight and fat findings originate from a short mouse proof-of-concept study.
A 2018 paper evaluated 5-Amino-1MQ in mice made obese through a high-fat diet. The in-vivo part of the study lasted 11 days.
Compared with vehicle-treated obese mice, the treated animals showed reductions in body-weight measures, white-adipose mass and adipocyte size. Total plasma cholesterol was also lower.
The researchers did not observe a corresponding reduction in food intake during that short experiment. This is the basis for many online statements claiming that the compound changes body composition without suppressing appetite.
That conclusion must remain within the mouse experiment. Eleven days of food-intake measurement in a controlled rodent model cannot establish how appetite, eating behaviour or body weight would respond in humans.
The study was designed as proof of concept for NNMT as a drug-development target. It was not a clinical trial and did not establish a human treatment protocol.
“Without appetite suppression” is often overstated
The accurate statement is that average food intake was not significantly altered in one short mouse study. It does not prove that human appetite would remain unchanged or that a human body-composition effect would occur.
5-Amino-1MQ Combined With a Reduced-Calorie Diet in Mice
Later research examined pharmacological NNMT inhibition alongside a diet change.
Diet-induced obese mice were switched from an obesity-promoting diet to a lower-fat diet and compared with groups receiving diet change alone or diet change plus 5-Amino-1MQ.
The combination group showed larger changes in body weight and whole-body adiposity than the diet-change-only group during the experimental period.
Researchers also examined metabolic and liver-related measurements. The results supported further investigation of NNMT inhibition as a drug-development concept.
A separate publication assessed the gut microbiome in the same broad experimental setting. Diet composition appeared to account for several of the observed microbiome differences.
These studies do not establish that adding 5-Amino-1MQ to a human calorie-reduction plan produces additional weight loss. Human appetite, adherence, metabolism, comorbidity and long-term risk cannot be modelled fully in laboratory mice.
Liver, Glucose and Insulin Research in Obese Mice
A 2024 study expanded the research to liver histology, metabolic markers and tissue distribution.
Diet-induced obese mice received vehicle or 5A1MQ for 28 days. Researchers measured body composition, glucose tolerance, insulin sensitivity, circulating markers and liver histology.
The higher-exposure group showed less body-weight and fat-mass gain than controls. The study also reported changes in glucose tolerance, insulin sensitivity and circulating insulin.
Liver findings included lower liver weight, reduced triglyceride content and less severe histological features of steatosis and inflammatory-cell infiltration in treated mice.
These were animal-model findings. They do not demonstrate that 5-Amino-1MQ treats diabetes, insulin resistance or metabolic dysfunction-associated steatotic liver disease in people.
The authors also noted that further optimisation was needed, including work relating to high clearance in mice and off-target activity against monoamine oxidase A.
Why the off-target point matters
A compound can appear selective at one concentration or in one test panel while interacting with additional enzymes at other exposures. Human off-target activity and interaction risks have not been adequately characterised.
Muscle-Regeneration and Ageing Research
Several studies have explored NNMT inhibition in old mice rather than in human muscle disease.
Aged Muscle Stem Cells
A 2019 study investigated skeletal-muscle tissue and muscle stem cells in aged mice. Researchers reported that NNMT inhibition affected senescent muscle-stem-cell activity and selected measures of regenerative capacity after experimental injury.
An experimentally injured mouse muscle is not equivalent to sarcopenia, frailty or impaired recovery in an older adult.
Exercise and Muscle Function
A 2024 study compared aged sedentary mice, exercised mice, inhibitor-treated mice and mice receiving both interventions.
The researchers measured grip strength, running capacity, torque, muscle characteristics, proteomics and metabolomics. Treated groups showed changes in several muscle-function measurements.
The research is relevant to drug-target discovery but does not establish a human strength, exercise-performance or healthy-ageing effect.
Several authors of the later 5A1MQ studies disclosed employment by or commercial interests in a company developing NNMT-targeted therapeutics. Commercial involvement does not invalidate the data, but it is relevant when assessing independence and the need for replication.
Pharmacokinetic and Bioavailability Research
Published pharmacokinetic information relates to rats and mice, not people.
A 2021 analytical study developed and validated an LC-MS/MS method to measure 5-amino-1-methylquinolinium in rat plasma and urine.
The method was applied to pharmacokinetic and oral-bioavailability experiments in rats. This demonstrated that the compound could be measured systematically after experimental administration.
The 2024 metabolic study also investigated plasma exposure and tissue distribution in mice after different experimental routes.
Mouse tissue measurements showed exposure in metabolically active tissues including adipose tissue, skeletal muscle and liver under the studied conditions.
Rat or mouse bioavailability cannot define human bioavailability. Species can differ substantially in absorption, transport, hepatic metabolism, renal handling and off-target effects.
No validated human pharmacokinetics
A human half-life, bioavailability, tissue distribution, metabolic pathway and exposure-response relationship have not been established through a published clinical programme.
What Human Evidence Exists?
No reliable clinical evidence for 5-Amino-1MQ was identified.
The scientific papers reviewed for this article involve enzyme systems, cultured cells, rats or mice.
No published Phase I trial establishing tolerability, human pharmacokinetics or dose escalation was identified.
No placebo-controlled human trial was identified for weight management, diabetes, fatty liver disease, sarcopenia, athletic performance or healthy ageing.
Online testimonials and self-reported experiences are not substitutes for clinical trials. They cannot verify product identity, control expectations, distinguish coincidence from causation or quantify adverse-event frequency.
Without controlled human exposure data, there is no validated human dose, treatment duration, monitoring programme, contraindication list or evidence-based interaction profile.
The central evidence gap
The compound has an interesting biological target and a growing mouse-research record. The necessary bridge from animal pharmacology to human safety and effectiveness has not been established.
5-Amino-1MQ Evidence at a Glance
The evidence is useful for target discovery but inadequate for human medical or weight-management claims.
| Research Question | Evidence Type | Current Finding | Main Limitation |
|---|---|---|---|
| Is 5-Amino-1MQ an NNMT inhibitor? | Enzyme and cell research | Inhibition and target engagement demonstrated | Experimental systems do not define human exposure |
| Is it a peptide? | Chemical structure | No, it is a quinolinium small molecule | Commercial catalogues frequently classify it incorrectly |
| Does it reduce 1-methylnicotinamide? | Cell and animal studies | Reductions reported | Clinical significance in humans is unknown |
| Does it affect adipocyte lipid accumulation? | Cultured-cell experiments | Reduced accumulation reported in selected models | Does not establish human fat loss |
| Does it alter body weight or fat mass? | Diet-induced obese mouse studies | Changes reported in several experiments | No controlled human trial |
| Does it suppress appetite? | Food-intake measurements in mice | No significant change in selected experiments | Cannot predict human appetite or eating behaviour |
| Does it affect glucose and insulin measurements? | Obese mouse model | Changes in tolerance and sensitivity measures reported | Does not establish diabetes treatment |
| Does it affect fatty-liver pathology? | Mouse liver histology | Less severe experimental pathology reported | No human liver-disease evidence |
| Does it improve muscle function? | Aged-mouse studies | Selected strength and regeneration changes reported | No evidence of benefit in older people |
| Is human safety established? | No adequate clinical programme identified | No | Unknown adverse-event frequency and long-term effects |
| Is it authorised in the UK? | Regulatory-source review | No marketing authorisation identified | Classification also depends on claims and intended use |
Important 5-Amino-1MQ Research Limitations
The evidence is broader than one experiment but remains entirely preclinical.
- 5-Amino-1MQ is frequently misclassified as a peptide.
- No controlled human trial was identified.
- No validated human dose has been established.
- No published human pharmacokinetic programme was identified.
- Most efficacy findings come from diet-induced obese mice.
- Mouse obesity does not reproduce all forms of human obesity.
- Several experiments were relatively short.
- Food intake in mice cannot establish human appetite effects.
- Body-weight changes do not reveal long-term safety.
- Cellular NAD measurements do not establish improved human energy or longevity.
- Altered liver histology in mice does not prove treatment of human liver disease.
- Muscle findings in old mice do not prove treatment of human sarcopenia.
- Off-target activity may vary by concentration and species.
- Long-term genotoxicity and carcinogenicity are not established in humans.
- Reproductive and developmental safety are not established.
- Interaction risks with medicines or other research compounds are unknown.
- Commercial research material may not match published study material.
- Several later papers involved authors with commercial development interests.
How 5-Amino-1MQ Research Material Should Be Tested
Analytical requirements should reflect its small-molecule salt chemistry rather than peptide testing alone.
LC-MS
Mass spectrometry should show an ion consistent with the 5-amino-1-methylquinolinium component.
Nuclear Magnetic Resonance
Proton and carbon NMR can help confirm the quinolinium ring, methyl group and amino-substitution pattern.
Iodide Confirmation
Where sold as the iodide salt, the counterion should be identified and quantitatively assessed.
Active-Content Measurement
The report should state whether the amount is calculated as free cation or complete salt.
Related Substances
Chromatography should resolve starting materials, positional isomers, degradation products and synthesis-related impurities.
Residual-Solvent Testing
Appropriate gas-chromatography or other validated methods should assess solvents used during synthesis and purification.
Moisture Content
Water content can affect the apparent assay and should be considered when reporting material on an as-is basis.
Finished-Material Stability
Stability studies should monitor assay, impurities, counterion balance and physical appearance under defined storage conditions.
What a Meaningful Certificate of Analysis Should Include
- Complete chemical name
- Declared salt and counterion
- Free-cation and salt molecular weights where relevant
- Batch number and manufacture date
- Observed LC-MS result
- NMR identity evidence
- Counterion result
- Quantitative active-content assay
- Chromatographic purity
- Named and unknown impurity results
- Residual-solvent results
- Water or loss-on-drying result
- Elemental or inorganic-impurity testing where appropriate
- Method references and acceptance limits
- Testing-laboratory identity
- A clear statement of tests not performed
Why “99% Purity” Is Not Enough
A single chromatographic percentage does not prove that the main peak is the correct positional isomer, that the counterion is correct, that the quantity is calculated properly or that residual solvents and inorganic impurities meet an appropriate specification.
It also does not establish pharmacological safety, human bioavailability or clinical effectiveness.
Safety and Product-Quality Uncertainties
There is no mature human safety record for 5-Amino-1MQ.
No Human Adverse-Event Programme
Without a controlled clinical development programme, the frequency and severity of possible adverse reactions cannot be estimated reliably.
Online reports cannot establish causation because the material may be mislabelled, contaminated, combined with other substances or used without objective monitoring.
Metabolic-System Uncertainty
NNMT participates in nicotinamide and methyl-donor metabolism. Sustained inhibition could have tissue-specific effects that short animal experiments do not fully capture.
Off-Target Activity
Later animal research acknowledged the need to optimise the compound in relation to clearance and off-target activity against monoamine oxidase A.
This does not establish a specific human interaction, but it reinforces the need for formal selectivity and safety testing.
Areas Without Adequate Human Evidence
- Cardiovascular safety
- Neurological and psychiatric effects
- Liver and kidney safety
- Effects on blood glucose in humans
- Effects on methylation pathways
- Genotoxicity
- Carcinogenicity
- Reproductive and developmental toxicity
- Use during pregnancy or breastfeeding
- Interactions with prescription medicines
- Interactions with supplements or research compounds
- Long-term exposure
Product-Quality Risks
- Incorrect quinolinium compound
- Wrong substitution position
- Incorrect counterion
- Incorrect active-content calculation
- Residual starting materials
- Residual solvents
- Degradation products
- Heavy-metal or inorganic contamination
- Mismatched certificate of analysis
- Uncontrolled storage and transport
Absence of published harm is not proof of safety
A compound without routine regulated human exposure may generate very few formal safety reports simply because there is no organised pharmacovigilance system.
5-Amino-1MQ and Regulation in the Peptides UK Market
Regulatory information checked on 21 July 2026.
No UK Marketing Authorisation Identified
No current UK marketing authorisation for a medicinal product containing 5-amino-1-methylquinolinium was identified in the official sources reviewed for this article.
It should not be presented as an approved medicine for obesity, weight management, diabetes, fatty liver disease, muscle loss, ageing or another medical condition.
The absence of marketing authorisation also means that no approved UK product information defines a human dose, indication, contraindication, adverse-effect profile or monitoring programme.
MHRA Borderline Classification
The MHRA assesses products using their ingredients, pharmacological properties, intended purpose and complete presentation.
A substance may fall within the definition of a medicinal product where it is presented as treating or preventing disease, or where it is intended to restore, correct or modify a physiological function through pharmacological, immunological or metabolic action.
Claims involving fat loss, obesity, glucose control, liver disease, sarcopenia, metabolism or anti-ageing could contribute to medicinal classification.
The MHRA may consider product pages, social-media posts, imagery, testimonials, instructions and implied claims. The phrase “Research Use Only” does not settle the position where the wider presentation points towards human use.
Advertising Restrictions
UK medicines legislation restricts advertising medicinal products where the required marketing authorisation, registration or certificate is not in force.
This section provides general regulatory education and does not constitute legal advice.
5-Amino-1MQ and Competitive Sport
Athletes should not assume that an unnamed experimental substance is permitted.
5-Amino-1MQ was not identified by name in the 2026 World Anti-Doping Agency list reviewed for this article.
However, the list includes an S0 category for pharmacological substances that are not addressed elsewhere and have no current approval by a governmental regulatory health authority for human therapeutic use.
This broad category can include experimental or designer substances. An athlete should obtain an authoritative ruling from the relevant anti-doping organisation rather than relying on a supplier’s statement.
A “research use” label does not provide protection from an anti-doping violation.
Common 5-Amino-1MQ Claims Examined
Most marketing statements start with a real experiment but extend the conclusion beyond the evidence.
“5-Amino-1MQ is a fat-loss peptide.”
Mouse studies reported changes in body weight and adiposity.
The compound is not a peptide, and no controlled human fat-loss trial was identified.
“It burns fat without affecting appetite.”
Food intake did not change significantly in selected short mouse experiments.
This does not establish a human appetite or weight-loss effect.
“It raises NAD levels.”
Increased intracellular NAD was reported in cultured adipocyte systems.
No controlled human study has established a beneficial NAD effect or its clinical significance.
“It improves insulin sensitivity.”
Glucose and insulin measurements changed in diet-induced obese mice.
This does not prove treatment of insulin resistance or diabetes in people.
“It reverses fatty liver.”
Treated obese mice showed less severe liver pathology in one research programme.
No human liver-disease trial was identified.
“It prevents age-related muscle loss.”
Muscle-function and regeneration findings have been reported in aged mice.
The evidence does not establish prevention or treatment of human sarcopenia.
“Oral bioavailability means it works in humans.”
Oral pharmacokinetics have been investigated in rats.
Animal absorption does not establish human bioavailability, effectiveness or safety.
“A 99% certificate proves the product is safe.”
Chemical purity can support laboratory characterisation.
It cannot establish human safety, correct counterion, effective exposure or clinical benefit.
5-Amino-1MQ Compared With Related Research Categories
The compounds below may appear together online but act through different biological systems.
| Substance or Category | Basic Identity | Research Target | Key Distinction |
|---|---|---|---|
| 5-Amino-1MQ | Quinolinium small molecule | NNMT inhibition | Entirely preclinical efficacy evidence identified |
| Nicotinamide | Vitamin B3 form | NAD precursor and NNMT substrate | Not an NNMT inhibitor |
| NMN | Nucleotide-related NAD precursor | NAD biosynthesis | Different structure and mechanism |
| GLP-1 receptor agonists | Peptide or peptide-like medicines | GLP-1 receptor | Some products have extensive human trials and regulatory approval |
| MOTS-c | Mitochondrial-derived peptide | Experimental metabolic signalling | A genuine peptide with a different research pathway |
| SLU-PP-332 | Small-molecule research compound | ERR-related transcriptional pathways | Not a peptide and not an NNMT inhibitor |
How to Assess 5-Amino-1MQ and Peptides UK Evidence Critically
Use this checklist before accepting a research, quality or regulatory claim.
- Does the source acknowledge that it is not a peptide?
- Is the full chemical name provided?
- Is the salt or counterion stated?
- Is the molecular weight for the cation or the complete salt?
- Was identity confirmed by LC-MS?
- Was the structure confirmed by NMR?
- Was the counterion tested?
- Does the certificate match the finished batch?
- Was the study conducted in cells, rats, mice or humans?
- How long did the study last?
- Was the model diet-induced obesity?
- Was food intake measured objectively?
- Were outcomes corrected for body-weight differences?
- Was the result independently replicated?
- Do the authors have commercial development interests?
- Was a human pharmacokinetic study performed?
- Was there a placebo-controlled human trial?
- Were adverse events monitored systematically?
- Is a mouse finding being presented as a human benefit?
- Is the claimed purpose authorised in the UK?
Medical and Editorial Review
This final article has been reviewed for medical context, evidence presentation, patient safety language and editorial clarity by the multidisciplinary panel below.
The reviewers and contributors are identified to provide clear authorship and accountability. Their inclusion does not represent endorsement of any research product, supplier, personal use, treatment claim or commercial statement discussed in this article.
Dr Laura Geige
Medical Director and Senior Aesthetics Practitioner at It’s Me & You Clinic, with a background in dentistry, medical aesthetics and cosmetic dermatology.
Read professional profile
Dr Rimas Geiga
Medical doctor with a special interest in nutritional sciences, dietology, metabolic health and evidence based preventative care.
Read professional profile
Dr Snieguole Geige
Dentist and medical doctor with experience across healthcare, preventative medicine and patient centred clinical standards.
Read professional profile
Dr Giedre Narkiene
Medical doctor and board certified dermatologist with expertise in medical and cosmetic dermatology, skin health and patient safety.
Read professional profile
Dr Veronika Matutyte
Medical doctor with training and professional experience in gerontology and healthcare management across clinical and hospital settings.
Read professional profile
Livija Samušienė
Qualified cosmetologist with a Bachelor of Health Sciences in cosmetology and a professional interest in skin health, acne and evidence based aesthetic care.
Read professional profile5-Amino-1MQ UK Frequently Asked Questions
Evidence-led answers about its identity, NNMT research, testing and UK status.
What is 5-Amino-1MQ?
It is a synthetic quinolinium small molecule studied as an inhibitor of nicotinamide N-methyltransferase.
Is 5-Amino-1MQ a peptide?
No. It has no amino-acid chain or peptide bonds. It is grouped with peptides mainly because research-peptide sellers frequently stock it.
What does the name 5-Amino-1MQ mean?
It refers to 5-amino-1-methylquinolinium: a quinolinium ring with an amino group at position five and a methyl group attached to the ring nitrogen.
What is NNMT?
NNMT is nicotinamide N-methyltransferase, an enzyme that uses a methyl donor to convert nicotinamide into 1-methylnicotinamide.
Why do researchers inhibit NNMT?
Researchers are examining whether altered NNMT activity affects nicotinamide metabolism, NAD-related pathways, methyl-donor balance and selected metabolic processes.
Has 5-Amino-1MQ been studied in humans?
No published controlled human trial was identified for this article. The main evidence involves cells, rats and mice.
Does 5-Amino-1MQ cause weight loss?
Body-weight and fat-mass changes were reported in diet-induced obese mice. Equivalent effects have not been established in people.
Does it suppress appetite?
Selected mouse studies did not find a significant reduction in food intake. This cannot establish how it affects human appetite.
Does it increase NAD?
Increased intracellular NAD was reported in selected cultured-cell experiments. A beneficial human NAD effect has not been demonstrated.
Has it been studied for diabetes?
Glucose-tolerance and insulin-sensitivity measurements changed in obese mice. No human diabetes-treatment evidence was identified.
Has it been studied for fatty liver disease?
Mouse studies reported changes in liver fat, inflammation and histology. This does not establish treatment of human liver disease.
Has it been studied for muscle loss?
Aged-mouse studies examined muscle regeneration and performance measurements. Human sarcopenia evidence was not identified.
Is oral bioavailability established?
Oral pharmacokinetics have been studied in rats. Human oral bioavailability has not been established.
What is 5-Amino-1MQ iodide?
It is the positively charged 5-amino-1-methylquinolinium component supplied with iodide as its counterion.
Why are two different molecular weights reported?
Approximately 159.21 Da refers to the free positively charged component, while approximately 286.11 g/mol includes the iodide counterion.
Is 5-Amino-1MQ approved in the UK?
No current UK marketing authorisation was identified.
Does “Research Use Only” settle the legal position?
No. The MHRA may consider the active substance, intended purpose, pharmacological action, claims, imagery and wider product presentation.
Is it permitted in competitive sport?
It was not identified by name in the reviewed WADA list, but the S0 category broadly covers non-approved pharmacological substances. Athletes should seek an official ruling.
What should a certificate of analysis include?
It should include chemical name, salt form, counterion, LC-MS identity, NMR evidence, assay, impurity profile, residual solvents, water content and batch information.
Does 99% HPLC prove the product is genuine?
No. It does not prove the correct isomer, counterion, active-content calculation, residual-solvent profile or human safety.
Are the human side effects known?
No reliable human safety profile has been established through controlled clinical development.
Does this article provide dosing or use instructions?
No. It does not provide preparation, dosing, oral-use, injection, cycling, stacking or personal-experimentation guidance.
Key Takeaways
- 5-Amino-1MQ is a small-molecule quinolinium compound rather than a peptide.
- It is studied as an inhibitor of nicotinamide N-methyltransferase.
- NNMT connects nicotinamide metabolism with the cellular methyl-donor system.
- Cell studies reported reduced 1-methylnicotinamide, altered NAD measurements and reduced lipid accumulation.
- Mouse studies reported changes in adiposity, glucose handling, liver pathology and muscle-function measurements.
- These findings do not establish human weight loss, diabetes treatment, liver treatment or healthy-ageing benefits.
- No published controlled human trial was identified.
- No validated human dose, half-life or safety programme was identified.
- The free cation and iodide salt have different reported molecular weights.
- A certificate should state the exact salt and basis of assay.
- No current UK marketing authorisation was identified.
- Research-use wording does not override UK medicines classification.
Relevant It’s Me & You Clinic Research Resources
Explore related evidence-led content and clinical contributor profiles.
Research Compounds and Peptides UK
Browse the wider educational series on chemical identity, preclinical evidence, analytical testing and UK regulation.
Browse the research education libraryMOTS-c Research
Compare this small-molecule NNMT inhibitor with a genuine mitochondrial-derived research peptide.
Browse related peptide guidesDr Rimas Geiga
Learn more about the clinic’s medical adviser with interests in metabolism, nutrition and healthy ageing.
View Dr Rimas Geiga’s profileDr Snieguole Geige
Explore the clinic’s approach to responsible medical education and evidence interpretation.
View Dr Snieguole Geige’s profileReferences
- PubChem. 5-Amino-1-methylquinolinium, CID 950107. PubChem compound record
- PubChem. 5-Amino-1-methylquinolinium iodide, NNMTi, CID 66522933. PubChem salt record
- Neelakantan H, Vance V, Wetzel MD, et al. Selective and membrane-permeable small molecule inhibitors of nicotinamide N-methyltransferase reverse high-fat-diet-induced obesity in mice. Biochemical Pharmacology. 2018;147:141–152. PMID: 29155147. Full-text article
- Neelakantan H, Brightwell CR, Graber TG, et al. Small molecule nicotinamide N-methyltransferase inhibitor activates senescent muscle stem cells and improves regenerative capacity of aged skeletal muscle. Biochemical Pharmacology. 2019;163:481–492. Full-text article
- Dimet-Wiley AL, Neelakantan H, Brightwell CR, et al. Combined nicotinamide N-methyltransferase inhibition and reduced-calorie diet normalizes body composition and enhances metabolic benefits in obese mice. Scientific Reports. 2021. Full-text article
- Dimet-Wiley AL, et al. Reduced calorie diet combined with NNMT inhibition establishes a distinct microbiome in diet-induced obese mice. Scientific Reports. 2022. PMID: 35013352. Full-text article
- Awosemo O, Neelakantan H, Watowich S, et al. Development and validation of LC-MS/MS assay for 5-amino-1-methyl quinolinium in rat plasma: application to pharmacokinetic and oral bioavailability studies. Journal of Pharmaceutical and Biomedical Analysis. 2021;204:114255. PMID: 34304009. PubMed record
- Babula JJ, Bui D, Stevenson HL, Watowich SJ, Neelakantan H. Nicotinamide N-methyltransferase inhibition mitigates obesity-related metabolic dysfunction. Diabetes, Obesity and Metabolism. 2024;26(11):5272–5287. PMID: 39161060. Full-text article
- Dimet-Wiley AL, Latham CM, Brightwell CR, et al. Nicotinamide N-methyltransferase inhibition mimics and boosts exercise-mediated improvements in muscle function in aged mice. Scientific Reports. 2024;14:15554. Full-text article
- Medicines and Healthcare products Regulatory Agency. Borderline products: how to tell if your product is a medicine. Updated 2 July 2026. MHRA guidance
- Medicines and Healthcare products Regulatory Agency. A guide to what is a medicinal product. Guidance Note 8. Updated May 2026. MHRA classification guide
- Human Medicines Regulations 2012, Regulation 279. Legislation.gov.uk
- World Anti-Doping Agency. 2026 Prohibited List. WADA 2026 list
- International Council for Harmonisation. ICH Q2(R2): Validation of Analytical Procedures. ICH analytical guideline
- UK Accreditation Service. Laboratory accreditation and ISO/IEC 17025 scope. UKAS guidance
